
Servier Mécénat 2020/2021 Annual Report
We are committed to therapeutic progress to serve patient needs with the help of healthcare professionals. We strive to provide future generations with a world where quality healthcare is available and accessible to all.
We undertake to provide innovative therapeutic solutions. Driven by a pioneering spirit, we dare, we strive, and we accomplish together.
We prepare for the future by embracing human and environmental dimensions. Our concern for the health and fulfillment of all is our driving force.
Every opportunity to work together contributes to the common good. Whoever we are, wherever we are, we grow and develop by working together, building on one another’s experiences and contributions.
The continuous development of the Group is vital. Whatever challenges we face, we are committed to keeping our promises.
Our R&D is specialized in 4 areas: oncology, cardiometabolism, neuroscience and immuno-inflammation. Within each of them, the Group has chosen to specialize in a limited number of pathologies where the medical needs are still great.
employees at 30
September 2023
countries in which
the Group’s medicines
are distributed.
of revenue from brand-name
medicines invested in
R&D
euros in revenue in 2022/2023
comprising €3.89 billion for brand-name
medicines and €1.29 billion
for generic medicines.
oncology,
cardiometabolism, neuroscience
and immuno-inflammation
Overall engagement score
among Servier Group
employees in 2023
Servier Medical Art is a medical image bank that we make available to illustrate your medical releases.
Servier Laboratories South Africa (Pty) Ltd
3rd Floor, Building J, Hertford Office Park
90 Bekker Road, Vorna Valley, Midrand
Tel: +27 (0) 861 700 900
Tel: +27 (0) 11 525 3400